Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof

• US 6,942,978 B1
• Filed: 08/28/2000
• Issued: 09/13/2005
• Est. Priority Date: 03/03/1999
• Status: Expired due to Term

• Current Assignee: Bioventures, LLC
• Original Assignee: The Board of Trustees of the University of Arkansas (University of Arkansas System)
• Inventors: O'Brien, Timothy J.
• Primary Examiner(s): Caputa, Anthony C.
• Assistant Examiner(s): Canella, Karen A.
• Application Number:
  US09/650,371
• Time in Patent Office: 1,842 Days
• Field of Search: 436/64, 436/813, 436/501, 436/503, 435/7.1, 435/7.2, 435/7.23, 435/7.4, 435/7.94
• US Class Current: 435/7.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C12N 9/6424 Serine endopeptidases (3.4.21)
• CPC Class Codes: C12N 9/6472 Cysteine endopeptidases (3.4.22)
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 33/574 for cancer

Abstract

The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment utilizing the DNA and/or protein disclosed herein.

Claims

1. A method for diagnosing cancer in an individual comprising the steps of:

(a) obtaining a biological sample from said individual;

(b) detecting a TADG-12 protein in said sample, wherein a TADG-12 protein is selected from the group consisting of SEQ ID NO;

2, SEQ ID NO;

4 and SEQ ID NO;

8, and wherein the presence of said TADG-12 protein in said sample is indicative of the presence of a cancer in said individual, and wherein the absence of said TADG-12 protein in said sample is indicative of the absence of a cancer in said individual.

2. The method of claim 1, wherein said biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells.

3. The method of claim 1, wherein said detection of a TADG-12 protein is by means selected from the group consisting of Western blot, dot blot, ELIZA sandwich assay, radioimmunoassay and flow cytometry.

4. The method of claim 1, wherein said cancer is selected from the group consisting of ovarian caner, breast cancer, lung cancer, colon caner, prostate cancer and other cancers in which TADG-12 is overexpressed.

5. A method for detecting malignant hyperplasia in a biological sample, comprising the steps of:

(a) isolating protein from said sample;

(b) detecting a TADG-12 protein in said sample, wherein a TADG-12 protein is selected from the group consisting of SEQ ID NO;

2, SEQ ID NO;

4 and SEQ ID NO;

8, and wherein the presence of said TADG-12 protein in said sample is indicative of the presence of malignant hyperplasia, and wherein the absence of said TADG-12 protein in said sample is indicative of the absence of malignant hyperplasia.

6. The method of claim 5, wherein said detection is by immunoaffinity to an antibody, wherein said antibody is directed against a TADG-12 protein.

7. The method of claim 5, wherein said biological sample is selected from the group consisting of blood, urine, saliva, tears, interstitial fluid, ascites fluid, tumor tissue biopsy and circulating tumor cells.